| 2026-07-28 17:20 |
8-K |
["3.02", "8.01", "9.01"] |
other |
0.05
|
Routine equity financing with Yorkville; no M&A signals present. |
SEC · detail |
| 2026-07-27 09:00 |
8-K |
["5.07", "8.01"] |
other |
0.05
|
Routine annual meeting voting results and equity financing update; no M&A signals. |
SEC · detail |
| 2026-07-21 16:05 |
8-K |
["1.01"] |
material agreement |
0.15
|
Jupiter entered into asset licensing agreement with PharmAla for ALA-002 development rights; not M&A-related. |
SEC · detail |
| 2026-06-30 17:07 |
8-K |
["5.02", "9.01"] |
other |
0.15
|
Board appointment of economist with healthcare advisory experience; no M&A signals present. |
SEC · detail |
| 2026-06-22 07:30 |
8-K |
["5.02", "9.01"] |
officer change |
0.15
|
Board member resignation with no disagreement cited; minimal M&A relevance. |
SEC · detail |
| 2026-06-05 16:30 |
8-K |
["5.02", "9.01"] |
officer change |
0.15
|
Routine executive compensation adjustments and promotions; no M&A-related signals detected. |
SEC · detail |
| 2026-05-21 09:51 |
8-K |
["1.01", "8.01", "9.01"] |
other |
0.05
|
Registered direct offering of common stock for $2.0M gross proceeds; no M&A signal. |
SEC · detail |
| 2026-05-20 09:45 |
8-K |
["7.01", "8.01"] |
material agreement |
0.72
|
Jupiter Neurosciences signed non-binding term sheet to acquire PharmAla's ALA-002 MDMA program rights for up to $56.7M. |
SEC · detail |